ArticleLeukemia & lymphoma2015

Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas.

Peter Martin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.